Arthritis Res Ther. 2011 Jun 20;13(3):114

Arthritis Res Ther. 2011 Jun 20;13(3):114. [Epub ahead of print]

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.

Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O.

Centre for Rheumatology, Royal Free Campus, University College Medical School, London, NW3 2PF, UK.

Abstract

Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). In clinical trials PAH-SSc has been grouped with other forms, including idiopathic PAH. The primary endpoint for most pivotal studies was improvement in exercise capacity. However, composite clinical endpoints that better reflect long-term outcome may be more meaningful. We discuss potential endpoints and consider why the same measures may not be appropriate for both idiopathic PAH and PAH-SSc due to inherent differences in clinical outcome and management strategies of these two forms of PAH. Failure to take this into account may compromise progress in managing PAH in SSc.

PMID:21699746